In this episode, Galbraith and David Fredrickson, EVP of Oncology Business Unit, join Bloomberg Intelligence analyst Sam Fazeli fresh from ASCO to discuss how AstraZeneca is navigating an ...

Three new cancer drugs could help AstraZeneca make a dent in its lofty ambition to become an $80 billion ... France, Germany, Italy, Japan, the U.K. and the U.S. each year, Dave Fredrickson, ...

David Fredrickson, executive vice president of AstraZeneca's oncology business, told CNBC that one in three patients who start treatment for this type of cancer are not able to receive a second ...

AstraZeneca Enters Deal With CSPC Pharma Valued at Up to $5.33 Billion. Global Pharma Stocks Fall as Trump Plans to Cut Drug Prices. AstraZeneca Sales, Earnings Rise; Faces China Tax Probe.